An evaluation of SOX2 and hTERC gene amplifications as screening markers in oral and oropharyngeal squamous cell carcinomas

Nadja Kokalj Vokač1,2*, Bogdan Čizmarevič2,3, Andreja Zagorac1, Boris Zagradišnik1 and Boštjan Lanišnik3

Abstract

Background: Oral and oropharyngeal squamous cell carcinomas (OSCC) are among the most common cancers. The poor survival rate among oral cancer patients can be attributed to several factors, one of them being lack of early detection. A key approach to this problem would be to detect potentially malignant lesion at their early stage. Using the FISH technique, oral brush cytology slides can be an easy and rapid screening approach for malignant cell detection. The present study was designed to detect hTERC and SOX2 amplifications in OSSC exfoliative tumor cells and evaluate whether those two gene amplifications might serve as a supportive biomarker in early detection and diagnosis of oral and oropharyngeal SCC.

Results: Brush biopsies were collected from exophytic and exulcerated oral and oropharyngeal lesions of the oral cavity of 71 patients and 22 healthy controls. FISH techniques using a TERC-specific DNA probe and a SOX2 DNA specific probe both combined with a centromere 3-specific control probe was performed on the cytology slides. A 100 squamous epithelial cell nuclei of the smears per slide were analysed. As abnormal FISH pattern were considered amplified and polyploid patterns.

From 71 brush biopsies of oropharynx and other locations in oral cavity analysed by FISH 49 were considered to be abnormal (69%). The over representation of polyploidy and/or TERC/SOX2 amplification in tumour samples was statistically significant when compared to controls (p = 0.01).

Conclusion: SOX2 and TERC gene amplifications are common in all squamous cell carcinomas and their detection in early stages could be crucial for early detection and more accurate prognosis. Our study strongly suggests that early detection by FISH on cytobrushed samples could be a possible non-invasive screening method even before a tissue biopsy is performed.

Keywords: SOX and hTERC gene amplifications, Brush biopsy, Oral, Oropharyngeal squamous cell carcinoma

Background

Oral and oropharyngeal squamous cell carcinomas (OSCCs) are among the most common cancers, and a major cause of mortality, with approximately 400,000 new cases and 200,000 deaths reported worldwide every year. For more than a half of OSCC patients the overall survival rate is only five years [1]. The poor survival rate among oral cancer patients can be attributed to several factors, including a lack of early detection. The established criteria of disease evaluation are biopsy diagnosis, lymph node involvement and stage, although they do not sufficiently account for the variability in clinical outcome. A key solution to this problem would be to detect potentially malignant lesions at an early stage. Tissue biopsy is performed only when the lesions become symptomatic. New methods are needed for the earlier detection of malignant cells, as are genetic markers for assessing disease aggressiveness and prognosis. Exfoliative cytology is an easy, non-invasive procedure and hence could be performed even on the suspicious lesion. Performing FISH on oral brush cytology slides can be a simple and rapid screening tool for malignant cell detection. In our study, the rate of
cancer cell detection was evaluated on OSCC cancer samples using this noninvasive technique.

During the last two decades, several genome screening approaches have been developed, including chromosome comparative genomic hybridization (CGH) and array-CGH. These techniques have made it possible to classify chromosomal aberrations at a high resolution, which can reveal frequent copy number gains and losses. Many such copy number aberrations harbor oncogenes or tumor suppressor genes and have therefore emerged as predictive and prognostic markers for tumors. Gains of chromosome arms 1q, 3q, 5p, 7p, 7q, 8q, 9q, 11q, 14q, 16p, 19q, and 20q and losses in 2p, 3p, 3q, 4q, 8p, 10p, 16q and 18q have been detected in OSCC samples, and genes located in those regions have been suggested as putative cancer-associated genes that might be altered during oral carcinogenesis [2-5]. Various proto-oncogene amplifications within critical regions have been detected, including TERT at 5p15, EGFR at 7p12, MYC at 8q24, and CCND1 at 11q13 [2,6].

A gain in the 3q26 region, which contains the hTERC and SOX2 genes, is frequently observed in various squamous cell carcinomas of mucosal origin. The human telomerase RNA component (hTERC) gene encodes an RNA subunit of telomerase that maintains the length of telomeres during cellular divisions and is activated in malignant diseases. TERC gene amplifications are described in the development of various SCCs, such as those in the larynx [7], cervix, esophagus and lungs. Our results, as well those of other authors, obtained from cervical smears have demonstrated that TERC gene amplifications correlate with high-grade squamous intraepithelial lesions that lead to invasive cervical cancer. SRY-related HMG-box 2 (SOX2) gene amplifications are also described in esophageal and lung squamous cell carcinomas [8]. This intronless gene encodes a member of the SOX family of transcription factors which control the expression of a number of genes involved in embryonic development, and cooperate in the induction of pluripotent stem cells [9-11]. Recently, independent studies have identified SOX2 as a lineage-survival oncogene [12] in SCCs of the lung based on an analysis of a large set of these tumors using high-resolution and high-throughput technologies [8,13]. In a study by Bass et al. [14], amplifications of SOX2 were detected in 23% of lung SCCs and 15% of esophageal SCCs. These amplifications resulted in presumably oncogenic SOX2 overexpression. Hussenet et al. [15] and Yuan et al. [16] detected SOX2 amplifications in lung SCCs at similar frequencies (20%). Because 3q26 amplifications are also regularly observed in oral cancer, the amplifications of the SOX2 gene could be an important diagnostic and prognostic marker. Using combined array-CGH and tissue microarray analysis Freire's et al. [3] detected a SOX2 gene copy number gain in 52% of OSCC tumors in, which a high expression of SOX2 was suspected to be correlated with gene copy number gain.

As described in our previous study on cervical preneoplastic lesions, TERC gene amplification is a high-risk prognostic factor for cervical cancer [17] and is likely an early event in tumorigenesis in squamous cell carcinoma. Here, we investigated whether TERC and SOX2 are appropriate markers for the early detection of OSCC. The present study was designed to detect hTERC and SOX2 amplifications in OSCC exfoliative tumor cells and evaluate whether these two gene amplifications might serve as a supportive bio-marker for the non-invasive detection and diagnosis of oral and oropharyngeal SCC.

Results
The study included 71 patients, mostly males (n = 54, 76%). Both genders had a comparable median age at diagnosis (Table 1). After study enrollment, 10 (0.14) patients died from their cancer and 14 (0.20) were lost to follow-up. All patients had histologically verified squamous cell carcinoma of the head and neck region, with tumours located mainly in the oral cavity (36 cases, 0.51; see Table 1 for details on tumour locations) or the oropharynx (27 cases, 0.38). The tumours were predominantly locally advanced cancers (48 stage IV cases, 0.68). The substantial lymph node involvement (44 cases, 0.62) may help explain the certain inconsistency between the TNM classification and disease stage data in Table 1. Distant metastases were present in the only two cases (one in the lung, one in the brain, Table 1). All patients received radical cancer treatment (surgery, chemo-therapy or radiotherapy), including two patients with a histologically confirmed carcinoma in situ who had their lesions surgically removed.

A total of 71 brush biopsies of the oropharynx and other locations in the oral cavity were analyzed by FISH using TERC, SOX2 and CEP-3 DNA probes. We considered polyploid and/or CEP-3 DNA ratios as abnormal. The intra and inter-tumor heterogeneity for the amplification of TERC/SOX2 locus was observed. We detected different FISH patterns in individual cases. A total of 49 of samples (69%) were considered abnormal, including 28, 10 and 5 cases in which 4–6, 6–9 and > 9 chromosomes were observed respectively. Twenty-seven of these were only polyploid (Figure 1d,g,h); 22 were polyploid and amplified, with CEP3: TERC/SOX2 FISH ratios that varied from 3:6–8, to 3–4:9–12 to 4:6–11 in the same tumor. (Figure 1b,c,e,f). Amplification only was detected in three tumors. The FISH pattern CEP3:TERC/SOX2 was 2:4 in these tumors (Figure 1a). The over- representation of polyploidy and/or TERC/SOX2 amplification in tumor samples was statistically significant compared to controls (p = 0.01, Table 2). When cancer samples were stratified according to the disease stage the presence of polypolidy
and/or amplification did not differ significantly, regardless of how the stages were combined. However, when tumors originating in the oropharynx were compared to tumors from all other locations, polyploidy and/or amplifications were observed at a significantly higher rate ($p = 0.0442$, Table 2).

Total of 22 control samples were tested, all except one were normal. In the abnormal case the smear was taken from a healthy part of the oral cavity of a patient with diagnosed OSCC.

**Conclusion**

In this study, we used two genes, SOX2 and hTERC, which are considered potential OSCC marker genes, to evaluate the FISH/cytobrush technique a screening method for cancer cell detection in smears from the oral and oropharyngeal cavity. Recurrent gene copy number aberrations are a frequent finding in OSCC and are believed to be critically involved in tumor formation. Studies using comparative genomic hybridisation and more recently, array-CGH have identified the human chromosomal region 3q21-q29 has being associated with decreased overall and disease-free survival in head and neck squamous cell carcinoma patients [[18], Choi S, Myers JN: Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res 2008, 87(1):14–32. Review]. Amplification of the genes located in this region, particularly SOX2 and TERC, could be useful markers for

---

**Table 1 Clinical data of patients with OSCC**

|                          | # (%) | Median age at diagnosis (range) | Observation time (range) |
|--------------------------|-------|--------------------------------|--------------------------|
| Women                    | 17 (0.24) | 57 (48–76) years               | 16 (3–27) months         |
| Men                      | 54 (0.76) | 58 (36–84) years               | 14 (3–24) months         |
| Deceased                 | 10 (0.14) |                                |                          |
| Current status unknown   | 14 (0.2)  |                                |                          |

**Tumour location**

| Location                  | # (%) |
|---------------------------|-------|
| Hypopharynx               | 5 (0.07) |
| Larynx                    | 2 (0.03) |
| Lips                      | 1 (0.01) |
| Mouth:                    | 36 (0.51) |
| Tongue                    | 14 (0.20) |
| Floor of the mouth        | 13 (0.18) |
| Retromolar trigone        | 3 (0.04) |
| Lower alveolus            | 3 (0.04) |
| Buccal mucosa             | 2 (0.03) |
| Upper alveolus            | 1 (0.01) |
| Oropharynx                | 27 (0.38) |

**TNM classification**

| Tumour | # (%) | Lymph node status | # (%) | Distant metastasis | # (%) |
|--------|-------|-------------------|-------|--------------------|-------|
| Tis    | 1 (0.01) | N0               | 27 (0.38) | M0    | 69 (0.97) |
| T1     | 5 (0.07) | N1 or higher     | 44 (0.62) | M1    | 2 (0.03) |
| T2     | 20 (0.28) |                |       |                   |       |
| T3     | 11 (0.25) |                |       |                   |       |
| T4     | 34 (0.48) |                |       |                   |       |

**Disease stage**

| Stage | # (%) | Histologic grading | # (%) |
|-------|-------|---------------------|-------|
| 0     | 1 (0.01) | Carcinoma in situ | 2 (0.03) |
| I     | 4 (0.06) | Grade 1            | 12 (0.17) |
| II    | 11 (0.15) | Grade 2            | 45 (0.63) |
| III   | 7 (0.10) | Grade 3            | 12 (0.17) |
| IVA   | 35 (0.49) |                   |       |
| IVB   | 11 (0.15) |                   |       |
| IVC   | 2 (0.03)  |                   |       |
malignant cell detection and could be used as prognostic markers in oral brush smears performed in the oral and oropharyngeal cavity.

We used cytobrush techniques to collect exfoliated cells from OSCC lesions. This non-invasive technique could be used as a suitable screening tool to detect suspicious oral cancer cases. Compared to tissue biopsy, this technique is also much more agreeable to the patient. The principle of the cytobrush technique was applied as early as 1951 [19] and has been used for RNA sampling [20], although it has not been used in combination with FISH. We used these two same techniques in a study of TERC gene amplifications in cervical cancer, in which we suggested that FISH analysis for TERC amplification should be included in the routine examination of cervical cancer as a screening method [17]. The only problem in evaluating the results obtained by this method is that with brush sampling, malignant cells are most likely not always collected in the smear. This could be the reason for at least some of the normal results obtained for our 22 cases.

Two genes were chosen for the screening, SOX2 and hTERC. An interphase FISH with a chromosome enumeration double-color DNA probe was used. Consistent with tissue biopsies and histopathological diagnoses, hTERC and SOX2 amplifications were not detected in normal oral and oropharyngeal tissues, except in one case, where the control smear was taken from the side opposite the tumor in the oral cavity, which could have been an actual positive case.

High SOX2 expression is detected in various oral squamous cell carcinomas (e.g., oral cavity and tongue); such expression is thought to be activated through gene copy number gain and is associated with poor prognosis [3,21]. Maier et al. [22] studied various types of SCCs and detected SOX2 gene amplification in all SCC types. They found that both the primary and the metastatic tumor cell populations showed SOX2 amplification. Their data suggest that SOX2 is targeted by relatively early events during tumor development, and thus, they postulated that activity of the SOX2 protein is more important in tumor initiation than tumor progression. In our study, statistically similar levels of SOX2 and TERC amplifications occurred in all stages of the disease regardless of lymph node status and tumor classification (Tables 1 and 2).

The TERC gene is a part of the telomerase complex, which encodes the telomerase RNA template. TERC is the most frequently observed amplified oncogene in cervical precancerous lesions and linked to high-grade cervical dysplasia and cancer [17,23-25]. High telomerase expression can be explained by the amplification of the TERC gene. The results of Lui Yu et al. [7] indicate that telomerase reactivation is an early event in laryngeal carcinogenesis and is already detectable at the stage of precancerous laryngeal epithelial changes. According to our results, showing that approximately 70% of OSSCs were detected by FISH using brush smears, we would predict that this technique could also be used to analyze the precancerous lesions as a screening tool in patients with suspected oral or oropharyngeal SCC.

In all histopathologically confirmed cases the same amplification detection result was obtained for both probes that were tested; i.e., when the TERC gene was
Table 2 FISH analysis of TERC/SOX2 loci vs. centromere 3 in OSCC patients according to the clinical characterization

| Clinical characterization | SOX2/TERC amplifications/polyploidy | Total abnormal FISH results | Odds ratio (95% confidence interval), p (two-tailed Fisher exact test) |
|---------------------------|------------------------------------|-----------------------------|------------------------------------------------------------------|
|                           | Normal | Polyploidy only | Amplification and polyploidy | Normal vs. total abnormal FISH results | Normal vs. Polyploidy only FISH results | Normal vs. amplification with polyploidy |
| Controls                  | 21     | 0               | 1                           | 1                                  | 46.77 (5.91-370) 0.00 | N/D² (N/D²) 0.00 | 21.00 (2.56-455) 0.00 |
| OSCC                      | 22     | 27              | 22                          | 49                                 | 1.29 (0.39 – 4.23), 0.78 | 1.25 (0.41-6.03) 0.76 | 1.00 (0.25-4.07) 1.00 |
| Stage: I, II, III         | 8      | 7               | 8                           | 15                                 | 0.69 (0.17-2.77), 0.76 | 0.98 (0.18-5.13) 1.00 | 0.48 (0.09-2.34) 0.49 |
| Stage: IV                 | 14     | 20              | 14                          | 34                                 | 2.00 (0.59-6.93), 0.29 | 1.83 (0.47-7.46) 0.38 | 2.22 (0.53-9.52) 0.34 |
| Stage: I, II              | 4      | 5               | 7                           | 12                                 | 2.00 (0.59-6.93), 0.29 | 1.83 (0.47-7.46) 0.38 | 2.22 (0.53-9.52) 0.34 |
| Stage: III, IV            | 18     | 22              | 15                          | 37                                 | 0.69 (0.17-2.77), 0.76 | 0.98 (0.18-5.13) 1.00 | 0.48 (0.09-2.34) 0.49 |
| Oropharynx                | 6      | 11              | 10                          | 21                                 | 2.00 (0.59-6.93), 0.29 | 1.83 (0.47-7.46) 0.38 | 2.22 (0.53-9.52) 0.34 |
| Outside oropharynx¹       | 16     | 16              | 12                          | 28                                 | 2.00 (0.59-6.93), 0.29 | 1.83 (0.47-7.46) 0.38 | 2.22 (0.53-9.52) 0.34 |

¹Listed in Table 1.
²Not determined.
amplified, the SOX2 gene was also amplified. These results confirm the observation of recurrent amplicons of the 3q26 region, where both genes are located, as described in various types of squamous cell carcinomas [Knuttila S, Björkqvist AM, Auto K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H, El-Rifai W, Hemmer S, Wasenius VM, Vidgren V, Zhu Y: DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 1998, 152(5):1107–1123. Review], [26]. Our results are in agreement with published array-CGH data [5] showing that extra copies of chromosome 3 regin are often detected, including all or only part of the 3q arm. Amplifications with a TERC/SOX2:CEP3 signal ratio >2 could be considered as abnormal results where true amplicons are observed, and the FISH signal occasionally appears as large dispersed areas of tested probe (Figure 1b,g). We observed abnormal polyploid cells in which almost the entire q arm of chromosome 3, including the centromere included, existed in 3, 4, 5, 6, 9 or more copies. From a prognostic point of view there is no difference between cells that are polyploid only, polyploid and amplified, or only amplified. Highly statistically significant results were detected only between all tumor cases and all controls.

Significantly different results were also obtained based on the location of the tumor. A greater number of positive cases were detected in the oropharynx compared to other locations of OSSC. This could be related to the high rate of HPV infection of esophageal carcinomas [27]. HPV infection may be responsible for the underlying chromosomal instability that can create a cellular environment where tetraploid cells can develop and proliferate. Tetraploidy often precedes the development of aneuploidy [28]. Our data show that there was a heterogeneous FISH pattern within and between tumors. These findings suggest that the higher rate of abnormal results in oropharyngeal tumors is related to polyploidies and HPV infections.

As we described in our previous study on cervical preneoplastic lesions, TERC gene amplification is a high risk prognostic factor for cervical cancer [17]. Maier et al. [22] demonstrated that SOX2 gene amplification is a common event in SCC of different organ sites, such as lung and cervix, and that it appears to be an early event in tumorigenesis. Cha et al. [29] analyzed the abundance of copy number alterations and various gene amplifications in the dysplastic transitional area of oral squamous cell carcinoma using array-CGH on fresh tissues. Those results appear to support our hypothesis that SOX2 and TERC gene amplifications are prognostic markers for OSSC and that amplifications are an early event in tumorigenesis. In the future research, these observations should be investigated on visible potentially precancerous lesions, such as erythroplakias.

In conclusion, SOX2 and TERC gene amplifications are common in all squamous cell carcinomas, and their detection in early stages could be crucial for the detection and more accurate prognosis of OSCCs. Our study strongly suggests that detection by FISH on cytobrushed samples could be a non-invasive screening method even before a biopsy is performed.

Methods

Tumors were classified according to location, lymph node status and histological differentiation. Tumor cells were collected from various locations within the oral cavity: lips, tongue, mouth, larynx, hypopharynx and oropharynx, Table 1. The controls were normal healthy individuals or buccal smears obtained from macroscopically uninvolved mucosal areas of the patients.

Brush biopsies were collected from ulcerated exophytic lesions of the oral cavity of 71 patients and 22 healthy controls. Two cytological smears were obtained from the area in question, and two were obtained from apparently normal mucosa near the lesion area using a Cytobrush Plus GT. A cytobrush cell collector was than rolled onto a glass slide. Slides were first treated with a hypotonic solution (0.0375 mol/M KCl) for 10 min at 37°C and than fixed with acetic acid and methanol (1:3) for 10 min at room temperature (RT). Slides were then dried for 30 min at 50°C and 30 min at 90°C, and than stored at −20°C until use.

Two probes were used for FISH: a combined TERC-specific DNA probe (RH17919−370Kb-RH10606) in red fluorescence emission and a centromere 3-specific control probe (D3Z1) in green fluorescence emission (ON hTERC 3q26/3q11 − Kreatech), or a SOX2 specific DNA probe (D3S3416−800Kb-D3S3957) in green combined with a centromere 3-specific probe in red (ZytoLight SPEC SOX2/CEN3 Dual Colour Probe - ZytoVision).

FISH was performed on slides pre-treated using 0.05% pepsin digestion for 30 min, fixation with 1% formaldehyde solution, and subsequent dehydration in an ethanol series (70%, 90%, 100%) and followed by air-drying. Slides were denaturated in 70% formamide for 3 min at 73°C, and probes were denaturated for 10 min at 73°C. Ten microliters of probe was applied to each slide under the 22×22 mm plastic cover slip and hybridized overnight in a moist chamber at 37°C.

The next day, the cover slips were gently removed and the slides were washed in 0.4×SSC + 0.05% Tween for 3 min at 73°C and in 2XSSC + 0.05% Tween for 2–60 s at RT. The slides were counter stained with DAPI and embedded in an anti-fadent solution. Images were acquired using an AxioImager.Z1 microscope (Zeiss, Germany) equipped with optical filters for DAPI, TRITC, and FITC (Chroma Technologies, Brattleboro, VT, USA).
The signals were evaluated by two independent screeners using an x63 objective. The signals were evaluated by screening the entire slide. Only morphologically abnormal nuclei with FISH signals for both colors were counted. Amplified and polyploid patterns were considered abnormal FISH patterns. Amplified FISH patterns had cells with two signals for CEP-3 and more than four signals for 3q26. Cells with more than 2 signals for CEP-3 and more than two signals for 3q26 with a ratio of 1:1 were considered polyploid. We evaluated at least 100 nuclei per slide and calculated the proportion of aberrant cells for each specimen. Images were analyzed using Cytovision 2.81 Version A.I. software (Applied Imaging, UK) (Figure 1).

For statistical analysis odds ratios (OR) with 95% confidence intervals (95%CI) were calculated, and the Fisher’s exact test was used to compare groups. Statistical significance was set at a P value less than 0.05.

This study was approved by the Ethics committee of the University Clinical Centre Maribor, where the study was performed, and signed informed consent was obtained from each patient.

Competing interests
We disclose no financial competing interests.
- In the past five years we have not received any reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future.
- We do not hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future.
- We do not hold or apply for any patents relating to the content of the manuscript. We do not receive reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript.
- We do not have any other financial competing interests. We disclose no Non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript.
- I and my co-authors ensure no competing interest.

Authors’ contributions
NKV have made conception and design of the study, carried out the molecular cytogenetic studies, acquisition of data, analysis, interpretation of data and wrote the manuscript. BC participated in the design of the study, collected the samples and the patients and helped to draft the manuscript. AZ carried out the molecular cytogenetic studies, acquisition of data, analysis, interpretation of data and wrote the manuscript. BZ performed the molecular cytogenetic studies, acquisition of data, analysis, interpretation of data and wrote the manuscript. BKK, JG, and MJ carried out the molecular cytogenetic studies, acquired data and wrote the manuscript. VK, NJS, and KK carried out the molecular cytogenetic studies, acquired data and wrote the manuscript. SV and MJJ participated in the design of the study, carried out the molecular cytogenetic studies, acquired data and wrote the manuscript. SNJ and JJS participated in the design of the study, carried out the molecular cytogenetic studies, acquired data and wrote the manuscript. JZ participated in the design of the study, carried out the molecular cytogenetic studies, acquired data and wrote the manuscript. KJ participated in the design of the study, carried out the molecular cytogenetic studies, acquired data and wrote the manuscript. KK participated in the design of the study, carried out the molecular cytogenetic studies, acquired data and wrote the manuscript. This work was supported by the Research Agency of Slovenia, grant no. P09-220.

Acknowledgements
This work was supported by the Research Agency of Slovenia, grant no. P09-220 Research Program. We thank Dr. Rajko Kavalar from the Department of Pathology, University Medical Centre Maribor, Slovenia, for his assistance with this study. This article was edited by American Journal Experts for grammar and style.

Author details
1Laboratory of Medical Genetics, University Medical Centre Maribor, Maribor, Slovenia. 2Medical Faculty, University of Maribor, Maribor, Slovenia. 3Department of Otorhinolaryngology, University Medical Centre Maribor, Maribor, Slovenia.

Received: 25 September 2013 Accepted: 11 December 2013
Published: 10 January 2014

References
1. Siegel R, Naishadham D, Jemal A: Cancer statistics. CA Cancer J Clin 2012, 62:10–29.
2. Baldwin C, Gamis C, Zhang L, Rosen MP, Iam WL: Multiple microaltered features detected at high frequency in oral cancer. Cancer Res 2005, 65:7561–7567.
3. Freier K, Knocke K, Fleischmacker C, Pungs S, Devenis F, Toedt G, Hofele C, Iocis S, Lichter P, Radlwimmer B: Recurrent copy number gain of transcription factor SOX2 and corresponding high expression in oral squamous cell carcinoma. Genes Chromosome Canc 2010, 49:9–16.
4. Uchida K, Oga A, Mano T, Mihara M, Kawauchi S, Furuya T, Ueyama Y, Sasaki K: Loss of 3q26.3 is an independent prognostic factor in patients with oral squamous cell carcinoma. Oncol Rep 2011, 26:463–469.
5. Hao JJ, Shi ZZ, Zhao ZX, Zhang Y, Gong T, Li CX, Zhan T, Cai Y, Dong JT, Fu SB, Zhan QM, Wang MR: Characterization of genetic rearrangements in esophageal squamous cell carcinoma cell lines by a combination of M-FISH and array-CGH: further confirmation of some split genomic regions in primary tumours. BMC Cancer 2012, 12:2637. doi:10.1186/1471-2407-12-367.
6. Gamis C, Cee BP, Zhang L, Rosen MP, Iam WL: Overexpression of LRP12, a gene contained within an 8q22 amplicon identified by high-resolution array-CGH analysis of oral squamous cell carcinomas. Oncogene 2004, 23(14):2582–2586.
7. Liu Y, Dong XL, Tian C, Liu HG: Human telomerase RNA component (hTERT) gene amplification detected by FISH in precancerous lesions and carcinoma of the larynx. Diagn Pathol 2012, 7:34. doi:10.1186/1746-1596-7-34.
8. Choi WW, Choi JS, Zheng LT, Lim YJ, Yoon HK, Kim YH, Wang YP, Lin YJ: Comparative genomic hybridization array analysis and real-time PCR reveals genomic alterations in squamous cell carcinomas of the lung. Lung Cancer 2007, 55:43–51.
9. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663–676.
10. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA: Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917–1920.
11. Wenming M, Messner A, Foreman R, Brambikin T, Ku M, Hochdedinger K, Bernstein BE, Jaenisch R: In vitro reprogrammung of fibroblasts into a pluripotent ES-cell-like state. Nature 2007, 448:318–324.
12. Berojkum R, Getz G, Nghiemphu L, Barretina J, Hsuieh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Xu T, Thomas RK, Shah K, Soto H, Perner S, Prensner J, Debiasi RM, Demichells F, Hatton C, Rubin MA, Garraway LA, Nelson SF, Liu I, Michel PS, Cloughesy TF, Meyerson M, Golub TA, Landers ES, Mellinghoff IK, Sellers WR: Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 2007, 104:20007–20012.
13. Pack SD, Kardera JD, Zhuang Z, Pak ED, Balan KV, Hwu P, Park WS, Pham T, Ault DO, Glaser M, Liotta L, Detera-Wadleigh SD, Wadleigh RG: Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations. Gene Chromosome Canc 1999, 25:160–168.
14. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gar-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Berojkum R, O’Kely M, Dutt A, Rozenblatt-Rosen O, Dzignycz P, Komisarof J, Chirieac LR, Lafargue CJ, Schiele V, Wibertz T, Mac C, Rao S, Nakagawa H, Stains BB, Lin L, Giordano TJ, Wistuba II: Multiple microalterations in oral squamous cell carcinomas. Genes Chromosome Canc 2010, 49:9–16.
15. Hussenet T, Dall S, Evinger J, Monga B, Jost B, Dembek D, Martinet N, Thibault C, Huesken J, Brambilla E, du Manoir S: SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 2010, 5(11):e8986.
16. Yuan P, Kardara H, Behrens C, Tang X, Woods D, Sols LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD, Wistuba II: Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One 2010, 5(6):e9912. doi:10.1371/journal.pone.0009912.
17. Kokalj-Vokac N, Kodic T, Erjavec-Skerget A, Zagorac A, Takac I: Screening of TERC gene amplification as an additional genetic diagnostic test in detection of cervical preneoplastic lesions. *Cancer Genet Cytogenet* 2009, 195(1):19–22. doi:10.1016/j.cancergencyto.2009.01.005.

18. Bockmühl U, Schlüns K, Küchler I, Petersen S, Petersen I: Genetic imbalances with impact on survival in head and neck cancer patients. *Am J Pathol* 2000, 157(2):369–378.

19. Montgomery PW, Von Haam E: A study of the exfoliative cytology in patients with carcinoma of the oral mucosa. *J Dent Res* 1951, 30(3):308–313.

20. Reboiras-López MD, Pérez-Sayáns M, Somoza-Martín JM, Gayoso-Díaz P, Barros-Angueira F, Gándara-Rey JM, García-García A: Comparison of the Cytobrush™, dermatological curette and oral CDx™ brush test as methods for obtaining samples of RNA for molecular analysis of oral cytology. *Cytopathology* 2012, 23(3):192–197. doi:10.1111/j.1365-2303.2011.00860.x. Epub 2011 Mar 17.

21. Lutao D, Yongmei Y, Xiaoyan X, Chuanxin W, Xuhua Z, Lili W, Xin Z, Wei L, Guxi Z, Shun W, Zhaogang D: Sox2 nuclear expression is closely associated with poor prognosis in patients with histologically node-negative oral tongue squamous cell carcinoma. *Oral Oncology* 2011, 47(8):709–713.

22. Maier S, Wilbertz T, Braun M, Scheible V, Reischl M, Mikut R, Menon R, Nikolov P, Petersen K, Beschorner C, Moch H, Kakies C, Prottel C, Bauer J, Soltermann A, Fend F, Staebler A, Lengerke C, Perner S: SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. *Hum Pathol* 2011, 42(8):1078–1088.

23. Andersson S, Wallin KL, Hellström AC, Morrison LE, Hjerpe A, Auer G, Gravitt PE, Larsson C, Wallin KL, Ried T, Larsson C, Heselmeyer-Haddad K: Frequent gain of the human telomerase gene TERC at 3q26 in cervical adenocarcinomas. *Br J Cancer* 2006, 95(3):331–338.

24. Andersson S, Sovijärvi P, Wangsa D, Hjerpe A, Johansson B, Auer G, Gravitt PE, Larsson C, Wallin KL, Ried T, Heselmeyer-Haddad K: Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears. *Am J Pathol* 2009, 175(5):1831–1847. doi:10.2353/ajpath.2009.090122.

25. Chen Q, Wang X, Ru Y, Chen S, Gao S, Xing L, Mi J, Wang Y, Xiao Z, Feng X: Amplification of the telomerase RNA component gene in the process of human esophageal carcinogenesis. *Tohoku J Exp Med* 2011, 224(3):299–104.

26. Gen Y, Yasui K, Zen Y, Zen K, Dohi O, Endo M, Tsuji K, Wakabayashi N, Itoh Y, Naito Y, Taniwaki M, Nakanuma Y, Okanoue T, Yoshikawa T: SOX2 identified as a target gene for the amplification at 3q26 that is frequently detected in esophageal squamous cell carcinoma. *Cancer Genet Cytogenet* 2010, 202(2):82–93.

27. Wang X, Tian X, Liu F, Zhao Y, Sun M, Chen D, Lu C, Wang Z, Shi X, Zhang Q, Zhang D, Shen Z, Li F, Harris CC, Cai H, Ke Y: Detection of HPV DNA in esophageal cancer specimens from different regions and ethnic groups: a descriptive study. *BMC Cancer* 2010, 10:191. doi:10.1186/1471-2407-10-19.

28. Ohalharsi AJ, Soteio R, Solarza-Luna G, Gonsebett ME, Guzman P, Mohar A, Eastmond DA: Tetraploidy and chromosomal instability are early events during cervical carcinogenesis. *Carcinogenesis* 2006, 27(2):337–343.

29. Cha JD, Kim HJ, Cha IH: Genetic alterations in oral squamous cell carcinoma progression detected by combining array-based comparative genomic hybridization and multiplex ligation-dependent probe amplification. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2011, 111(5):594–607. doi:10.1016/j.tripleo.2010.11.020.